Document Type
Article
Publication Date
12-1-2024
Abstract
Antenatal corticosteroids have long been considered one of the most important antenatal therapies available for pregnant patients at risk of preterm birth based on the associated reduction of neonatal morbidity and mortality following their administration. However, despite decades of research since their incorporation into routine clinical practice, a number of key questions related to antenatal corticosteroid use remain. These include evaluating the impact of antenatal corticosteroids at gestational ages outside of the previously recommended window of 24 0/7–33 6/7 weeks of gestation, determining factors associated with optimal steroid timing in order to reduce unnecessary exposure, alterations in its dosing regimen, and their long-term impact. The purpose of this document is to review the latest evidence on antenatal corticosteroids and recent developments in emerging topics related to their use.
Recommended Citation
Gulersen, Moti and Gyamfi-Bannerman, Cynthia, "What Is the Evidence? Updates in the Use of Antenatal Corticosteroids for Patients at Risk of Preterm Birth" (2024). Department of Obstetrics and Gynecology Faculty Papers. Paper 118.
https://jdc.jefferson.edu/obgynfp/118
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Language
English
Included in
Health Services Research Commons, Obstetrics and Gynecology Commons, Therapeutics Commons
Comments
This article is the author's final published version in European Journal of Obstetrics and Gynecology and Reproductive Biology: X, Volume 24, December 2024, Article number 100352.
The published version is available at https://doi.org/10.1016/j.eurox.2024.100352.
Copyright © 2024 The Authors